Atezolizumab Induced Sicca Syndrome: A Case Report
Aiswarya Wilson
Department of Pharmacy Practice, St Joseph's College of Pharmacy, Cherthala, Kerala, India.
Vidya S
Department of Pharmacy Practice, St Joseph's College of Pharmacy, Cherthala, Kerala, India.
Siby Joseph *
Department of Pharmacy Practice, St Joseph's College of Pharmacy, Cherthala, Kerala, India.
Madhu C S
Department of Oncology, Lourdes Hospital and Post Graduate Research Centre, Cochin, Kerala, India.
Aditya V Boney
Department of Oncology, Lourdes Hospital and Post Graduate Research Centre, Cochin, Kerala, India.
*Author to whom correspondence should be addressed.
Abstract
Immune checkpoint inhibitors have made a drastic improvement in the management of cancer though it is not completely free from adverse outcomes, which may be due to the dysregulated immune system. These negative outcomes following treatment with checkpoint inhibitors are collectively known as immune related adverse events. Though there are many case reports of sicca syndrome induced by immune checkpoint inhibitors, Atezolizumab was free from this adverse outcome. In our patient care setting we observed sicca syndrome in one elderly patient during treatment with Atezolizumab. It was managed with corticosteroids; pilocarpine eye drops and other standard care of treatment.
Keywords: Atezolizumab, immune checkpoint inhibitors, immune related adverse events, sicca syndrome